Volume 20 Issue 3
Mar.  2022
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2022  >  20(3): 395-398
GAO Long-fei, LIU Jian. Prognostic analysis of different treatments for locally advanced cervical cancer[J]. Chinese Journal of General Practice, 2022, 20(3): 395-398. doi: 10.16766/j.cnki.issn.1674-4152.002361
Citation: GAO Long-fei, LIU Jian. Prognostic analysis of different treatments for locally advanced cervical cancer[J]. Chinese Journal of General Practice, 2022, 20(3): 395-398. doi: 10.16766/j.cnki.issn.1674-4152.002361
shu

Prognostic analysis of different treatments for locally advanced cervical cancer

doi: 10.16766/j.cnki.issn.1674-4152.002361

  • Department of Oncology and Gynaecology, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China

Funds:

 KJ2019A0363

  • Received Date: 2021-02-21
    Available Online: 2022-08-13
    Abstract
  •   Objective  To investigate the effect of neoadjuvant chemotherapy and radical surgery (NACT+RS) and surgery alone (radical surgery, RS) on the prognosis of locally advanced cervical cancer.  Methods  From January 2013 to December 2015, 119 patients with locally advanced cervical cancer were divided into the NACT+RS group (n=74) and the RS group (n=45). According to the curative effect of chemotherapy, the NACT+RS group was divided into an effective group (n=45) and an ineffective group (n=29). The operation time, intraoperative blood loss, post-operative pathological features and 5-year survival between the NACT+RS and RS groups were compared, and the post-operative pathological features and 5-year survival between the NACT effective group and the RS group were compared to evaluate the effect of NACT combined operation on patient survival.  Results  No significant difference in intraoperative blood loss, operation time, lymph node metastasis, myometrial invasion and 5-year survival rate was found between the NACT+RS and RS groups. The amount of intraoperative blood loss in NACT+RS group was significantly less than that in RS group (P < 0.05). Compared with that in the NACT effective group, the positive rate of lymph node metastasis in the RS group was 4.4% and 17.8%, respectively, and the difference was statistically significant (χ2=4.050, P=0.044). In addition, the deep muscle infiltration rate was 20.0%, 55.6%, respectively, and the difference was statistically significant (χ2=12.101, P=0.001). The 5-year survival rate of the NACT effective group was 93.3%, whereas that of the RS group was 73.3% (χ2=6.480, P=0.011).  Conclusion  Compared with simple operation, neoadjuvant chemotherapy combined with surgery can reduce lymph node metastasis and myometrial invasion and improve the long-term prognosis of patients.

     

    • FullText(HTML)
  • loading
    • References(19)
  • [1]
    BHATLA N, AOKI D, SHARMA D N, et al. Cancer of the cervix uteri[J]. Int J Gynaecol Obstet, 2018, 143(Suppl 2): 22-36. https://pubmed.ncbi.nlm.nih.gov/30306584/
    [2]
    李雪, 孔为民. 局部晚期子宫颈癌治疗的研究进展[J]. 中华妇产科杂志, 2015, 50(5): 388-390.

    LI X, KONG W M. Research progress in the treatment of locally advanced cervical cancer[J]. Journal of Chinese Department of Obstetrics and Gynecology, 2015, 50(5): 388-390.
    [3]
    KOH W J, ABU-RUSTUM N R, BEAN S, et al. Cervical cancer, Version 3.2019, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2019, 17(1): 64-84. doi: 10.6004/jnccn.2019.0001
    [4]
    PHILLIPS P, PHILLIPS J. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer[J]. Clin Nurse Spec, 2017, 31(4): 189-190. doi: 10.1097/NUR.0000000000000304
    [5]
    LEE J, KIM T H, KIM G E, et al. Neoadjuvant chemotherapy followed by surgery has no therapeutic advantages over concurrent chemoradiotherapy in International Federation of Gynecology and Obstetrics stage ⅠB-ⅡB cervical cancer[J]. J Gynecol Oncol, 2016, 27(5): e52. doi: 10.3802/jgo.2016.27.e52
    [6]
    GUPTA S, MAHESHWARI A, PARAB P, et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage ⅠB2, ⅡA, or ⅡB squamous cervical cancer: A randomized controlled trial[J]. J Clin Oncol, 2018, 36(16): 1548-1555. doi: 10.1200/JCO.2017.75.9985
    [7]
    HSIEH H Y, HUANG J W, LU C H, et al. Definite chemoradiotherapy is a competent treatment option in FIGO stage ⅠB2 cervical cancer compared with radical surgery +/- neoadjuvant chemotherapy[J]. J Formos Med Assoc, 2019, 118(1 Pt 1): 99-108.
    [8]
    HE Y, ZHAO Q, GENG Y N, et al. Analysis of short-term efficacy as defined by RECIST and pathological response of neoadjuvant chemotherapy comprised paclitaxel and cisplatin followed by radical surgery in patients with locally advanced cervical cancer: A prospective observational study[J]. Medicine (Baltimore), 2018, 97(22): e10913. doi: 10.1097/MD.0000000000010913
    [9]
    庄晴晴, 王常玉. 新辅助化疗与单纯手术在局部晚期宫颈癌患者中的疗效对比分析[J]. 现代妇产科进展, 2016, 25(7): 487-490. https://www.cnki.com.cn/Article/CJFDTOTAL-XDFC201607002.htm

    ZHUANG Q Q, WANG C Y. Comparative analysis of the efficacy of neoadjuvant chemotherapy and simple surgery in patients with locally advanced cervical cancer[J]. Advances in Modern Obstetrics and Gynecology, 2016, 25(7): 487-490. https://www.cnki.com.cn/Article/CJFDTOTAL-XDFC201607002.htm
    [10]
    GONG L, ZHANG J W, YIN R T, et al. Safety and efficacy of neoadjuvant chemotherapy followed by radical surgery versus radical surgery alone in locally advanced cervical cancer patients[J]. Int J Gynecol Cancer, 2016, 26(4): 722-728. doi: 10.1097/IGC.0000000000000658
    [11]
    朱安娜, 关明飞, 马银萍, 等. 局部晚期宫颈癌(ⅠB2及ⅡA2期)不同治疗模式的对比研究[J]. 中国妇产科临床杂志, 2020, 21(3): 258-261. https://www.cnki.com.cn/Article/CJFDTOTAL-FKLC202003012.htm

    ZHU A N, GUAN M F, MA Y P, et al. Comparative study on different treatment modes of locally advanced cervical cancer (stage Ⅰ B2 and Ⅱ A2)[J]. Chinese Journal of Obstetrics and Gynecology, 2020, 21(3): 258-261. https://www.cnki.com.cn/Article/CJFDTOTAL-FKLC202003012.htm
    [12]
    YAN W, SI L, DING Y, et al. Neoadjuvant chemotherapy does not improve the prognosis and lymph node metastasis rate of locally advanced cervical squamous cell carcinoma: A retrospective cohort study in China[J]. Medicine (Baltimore), 2019, 98(39): e17234. doi: 10.1097/MD.0000000000017234
    [13]
    YIN M, ZHAO F, LOU G, et al. The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with radical surgery alone or concurrent chemoradiotherapy on locally advanced-stage cervical cancer[J]. Int J Gynecol Cancer, 2011, 21(1): 92-99.
    [14]
    邹婷婷, 符淳. ⅠB2~ⅡB期局部晚期宫颈癌新辅助化疗疗效分析[J]. 湖南师范大学学报(医学版), 2019, 16(2): 42-44. doi: 10.3969/j.issn.1673-016X.2019.02.013

    ZOU T T, FU C. Analysis of the efficacy of neoadjuvant chemotherapy in stage ⅠB2 ~ ⅡB locally advanced cervical cancer[J]. Journal of Hunan normal University (Medical Edition), 2019, 16(2): 42-44. doi: 10.3969/j.issn.1673-016X.2019.02.013
    [15]
    ZHAO H, HE Y, YANG S L, et al. Neoadjuvant chemotherapy with radical surgery vs radical surgery alone for cervical cancer: A systematic review and meta-analysis[J]. Onco Targets Ther, 2019, 12: 1881-1891. doi: 10.2147/OTT.S186451
    [16]
    LI R, LU S T, SI J G, et al. Prognostic value of responsiveness of neoadjuvant chemotherapy before surgery for patients with stage ⅠB(2)/ ⅡA(2) cervical cancer[J]. Gynecol Oncol, 2013, 128(3): 524-529. doi: 10.1016/j.ygyno.2012.11.006
    [17]
    陆婕, 吴晓杰, 朱巍立. 根治性宫颈癌手术患者盆腔淋巴结转移和预后的影响因素分析[J]. 中华全科医学, 2017, 15(2): 270-273. doi: 10.16766/j.cnki.issn.1674-4152.2017.02.027

    LU J, WU X J, ZHU W L. Analysis of influencing factors of pelvic lymph node metastasis and prognosis in patients with radical cervical cancer[J]. Chinese General Medicine, 2017, 15(2): 270-273. doi: 10.16766/j.cnki.issn.1674-4152.2017.02.027
    [18]
    安菊生, 赵羽西, 宋艳, 等. Ⅰb2和Ⅱa2期子宫颈鳞癌新辅助化疗的疗效及影响预后的术后病理因素分析[J]. 中华妇产科杂志, 2019, 54(10): 673-674.

    AN J S, ZHAO Y X, SONG Y, et al. Analysis of effects and postoperative clinicopathological prognosis factors of neoadjuvant chemotherapy in patients with stageⅠb2 andⅡa2 squamous cell carcinoma of the cervix[J]. Chinese Journal of Obstetrics and Gynecology, 2015, 50(5): 388-390.
    [19]
    邹婷婷, 郑春莹, 张志邦, 等. 187例ⅠB2和ⅡA2期宫颈癌新辅助化疗疗效及预后的影响因素[J]. 中南大学学报(医学版), 2020, 45(3): 297-304. https://www.cnki.com.cn/Article/CJFDTOTAL-HNYD202003013.htm

    ZOU T T, ZHENG C Y, ZHANG Z B, et al. Neoadjuvant chemotherapy efficacy and prognostic factors in 187 cervical cancer patients with ⅠB2 and ⅡA2 stage[J]. Journal of Central South University (Medical Science), 2015, 50(5): 388-390. https://www.cnki.com.cn/Article/CJFDTOTAL-HNYD202003013.htm
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (250) PDF downloads(2) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return